ABCA1: A Therapeutic Target for Improving Cholesterol Homeostasis in Peripheral Neuropathies
Biomolecules · 2026
DOI: 10.3390/biom16020332 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Biomolecules, 2026. Verfasst von Yeon Hwa Woo und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Physiology and Cell Biology, School of Medicine, University of Nevada, Reno, NV 89557, USA. Hauptthemen laut MEDLINE: ATP Binding Cassette Transporter 1, Cholesterol, Peripheral Nervous System Diseases. Die Arbeit nennt 89 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIH-NINDS, Facial Pain Research Foundation, Inc.
Abstract (Originalsprache)
ATP-binding cassette A1 (ABCA1) is a critical molecule in facilitating cholesterol transport in a variety of organs. In the nervous system, cholesterol supply is essential and rate-limiting for myelin biogenesis, which underlies efficient conduction of nerve impulses. When myelin is damaged or improperly formed due to genetic defects, a host of neurological symptoms may arise. A rare form of peripheral neuropathy in Tangier disease (TD) patients is associated with autosomal recessive mutations in ABCA1. Accordingly, when ABCA1 loses its function due to misexpression, the neuropathic phenotype is over-represented. Independently, studies have revealed the altered expression of ABCA1 and dysregulation of cholesterol metabolism in a host of inherited peripheral neuropathies engaging the Peripheral Myelin Protein 22 (PMP22), suggesting shared pathophysiology. While the role of ABCA1 has not been investigated broadly in peripheral nerves, the transporter molecule is a therapeutic target for human disorders, including multiple sclerosis and Alzheimer’s disease. Investigations in rodent models of type 1 Charcot–Marie–Tooth (CMT) neuropathies support the candidacy of this cholesterol transporter as a therapeutic target in efforts of peripheral myelin repair. Ongoing preclinical studies in central and peripheral nervous system disease models will provide critical information on the importance of ABCA1 as a target for disease modifying intervention.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Physiology and Cell Biology, School of Medicine, University of Nevada, Reno, NV 89557, USA.
- Artery Therapeutics, Inc., 10 Duberstein Dr, Suite A, San Ramon, CA 94583, USA.
ORCID-Profile: Natalie E Schmidt, Lucia Notterpek
Förderung
- NIH-NINDS
- Facial Pain Research Foundation, Inc
Zitieren
APA
Woo, Y. H., Schmidt, N. E., Johansson, J. O., & Notterpek, L. (2026). ABCA1: A Therapeutic Target for Improving Cholesterol Homeostasis in Peripheral Neuropathies. Biomolecules. https://doi.org/10.3390/biom16020332
Vancouver
Woo YH, Schmidt NE, Johansson JO, Notterpek L. ABCA1: A Therapeutic Target for Improving Cholesterol Homeostasis in Peripheral Neuropathies. Biomolecules. 2026. doi:10.3390/biom16020332
BibTeX
@article{Woo2026,
author = {Woo, Yeon Hwa and Schmidt, Natalie E and Johansson, Jan O and Notterpek, Lucia},
title = {ABCA1: A Therapeutic Target for Improving Cholesterol Homeostasis in Peripheral Neuropathies},
journal = {Biomolecules},
year = {2026},
doi = {10.3390/biom16020332}
}
EUVIMED